Domingo A Pascual-Figal1, Andreu Ferrero-Gregori2, Ines Gomez-Otero3, Rafael Vazquez4, Juan Delgado-Jimenez5, Jesus Alvarez-Garcia2, Juan R Gimeno-Blanes6, Fernando Worner-Diz7, Alfredo Bardají8, Luis Alonso-Pulpon9, Jose Ramon Gonzalez-Juanatey3, Juan Cinca2. 1. Servicio de Cardiología, Hospital Universitario Virgen de la Arrixaca, Facultad de Medicina, Universidad de Murcia, CIBERCV, Murcia, Spain. Electronic address: dpascual@um.es. 2. Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, CIBERCV, Barcelona, Spain. 3. Servicio de Cardiología y Unidad Coronaria, Complejo Hospitalario Universitario de Santiago de Compostela, CIBERCV, Santiago de Compostela, A Coruña, Spain. 4. Servicio de Cardiologia, Hospital Puerta del Mar, Cadiz, Spain. 5. Servicio de Cardiología, Hospital Universitario 12 de Octubre, CIBERCV, Madrid, Spain. 6. Servicio de Cardiología, Hospital Universitario Virgen de la Arrixaca, Facultad de Medicina, Universidad de Murcia, CIBERCV, Murcia, Spain. 7. Servicio de Cardiologia, Hospital Arnau de Vilanova, Lleida, Spain. 8. Servico de Cardiologia, Hospital Juan XXIII, Tarragona, Spain. 9. Servico de Cardiologia, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain.
Abstract
BACKGROUND: The intermediate group of patients with heart failure (HF) and mid-range left ventricular ejection fraction (HFmrEF) may constitute a specific phenotype, but a direct evidence is lacking. This study aimed to know whether this HF category is accompanied by a particular clinical phenotype and prognosis. METHODS AND RESULTS: This study includes 3446 ambulatory patients with chronic HF from two national registries. According to EF at enrollment, patients were classified as reduced (HFrEF, <40%), mid-range (HFmrEF, 40-49%) or preserved (HFpEF, ≥50%). Patients were followed-up for a median of 41months and the specific cause of death was prospectively registered. Patients with HFmrEF represented 13% of population and they exhibited a phenotype closer to HFrEF, except for a higher rate of coronary revascularization and diabetes, and a less advanced HF syndrome. The observed all-cause mortality was higher among HFrEF (33.0%), and similar between HFmrEF (27.8%) and HFpEF (28.0%) (p=0.012); however, the contribution of each cause of death differed significantly between categories (p<0.001). After propensity score matching, the risk of cardiovascular death, HF death or sudden cardiac death did not differ between HFmrEF and HFrEF in paired samples; however, patients with HFmrEF were at higher risk of cardiovascular death (sHR 1.71, 95% CI 1.13-2.57, p=0.011) and sudden cardiac death (sHR 2.73, 95% CI 1.07-6.98, p=0.036) than patients with HFpEF. CONCLUSIONS: Patients in the intermediate category of HFmrEF conform a phenotype closer to the clinical profile of HFrEF, and associated to higher risk of sudden cardiac death and cardiovascular death than patients with HFpEF.
BACKGROUND: The intermediate group of patients with heart failure (HF) and mid-range left ventricular ejection fraction (HFmrEF) may constitute a specific phenotype, but a direct evidence is lacking. This study aimed to know whether this HF category is accompanied by a particular clinical phenotype and prognosis. METHODS AND RESULTS: This study includes 3446 ambulatory patients with chronic HF from two national registries. According to EF at enrollment, patients were classified as reduced (HFrEF, <40%), mid-range (HFmrEF, 40-49%) or preserved (HFpEF, ≥50%). Patients were followed-up for a median of 41months and the specific cause of death was prospectively registered. Patients with HFmrEF represented 13% of population and they exhibited a phenotype closer to HFrEF, except for a higher rate of coronary revascularization and diabetes, and a less advanced HF syndrome. The observed all-cause mortality was higher among HFrEF (33.0%), and similar between HFmrEF (27.8%) and HFpEF (28.0%) (p=0.012); however, the contribution of each cause of death differed significantly between categories (p<0.001). After propensity score matching, the risk of cardiovascular death, HF death or sudden cardiac death did not differ between HFmrEF and HFrEF in paired samples; however, patients with HFmrEF were at higher risk of cardiovascular death (sHR 1.71, 95% CI 1.13-2.57, p=0.011) and sudden cardiac death (sHR 2.73, 95% CI 1.07-6.98, p=0.036) than patients with HFpEF. CONCLUSIONS:Patients in the intermediate category of HFmrEF conform a phenotype closer to the clinical profile of HFrEF, and associated to higher risk of sudden cardiac death and cardiovascular death than patients with HFpEF.
Authors: Nuria Farré; Josep Lupon; Eulàlia Roig; Jose Gonzalez-Costello; Joan Vila; Silvia Perez; Marta de Antonio; Eduard Solé-González; Cristina Sánchez-Enrique; Pedro Moliner; Sonia Ruiz; C Enjuanes; Sonia Mirabet; Antoni Bayés-Genís; Josep Comin-Colet Journal: BMJ Open Date: 2017-12-21 Impact factor: 2.692
Authors: Theodora Nikolaidou; Nathan A Samuel; Carl Marincowitz; David J Fox; John G F Cleland; Andrew L Clark Journal: Ann Noninvasive Electrocardiol Date: 2019-10-11 Impact factor: 1.468
Authors: Miriam A M Nji; Scott D Solomon; Lin Yee Chen; Amil M Shah; Elsayed Z Soliman; Aniqa B Alam; Vinita Subramanya; Alvaro Alonso Journal: Int J Cardiol Date: 2021-07-08 Impact factor: 4.039